Meridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 Shares

Meridian Bioscience, Inc. (NASDAQ:VIVO) Director John Mccune Jr. Rice bought 1,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were bought at an average cost of $14.75 per share, for a total transaction of $14,750.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Meridian Bioscience, Inc. (NASDAQ:VIVO) opened at $14.85 on Thursday. The stock has a market cap of $634.61, a P/E ratio of 29.12 and a beta of 0.98. The company has a quick ratio of 4.04, a current ratio of 5.85 and a debt-to-equity ratio of 0.30. Meridian Bioscience, Inc. has a 52 week low of $12.30 and a 52 week high of $16.45.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, January 25th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.01. The company had revenue of $52.30 million for the quarter, compared to analysts’ expectations of $49.00 million. Meridian Bioscience had a net margin of 10.46% and a return on equity of 17.09%. The business’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 EPS. research analysts expect that Meridian Bioscience, Inc. will post 0.69 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Monday, February 5th will be paid a $0.125 dividend. The ex-dividend date of this dividend is Friday, February 2nd. This represents a $0.50 annualized dividend and a dividend yield of 3.37%. Meridian Bioscience’s dividend payout ratio is currently 98.04%.

Several equities analysts have commented on the stock. BidaskClub cut shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, February 3rd. Canaccord Genuity reissued a “hold” rating and set a $14.00 target price on shares of Meridian Bioscience in a research note on Friday, October 13th. Finally, Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Friday, November 17th.

Several institutional investors and hedge funds have recently made changes to their positions in VIVO. Schwab Charles Investment Management Inc. grew its stake in shares of Meridian Bioscience by 2.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 401,992 shares of the company’s stock worth $6,332,000 after purchasing an additional 10,816 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Meridian Bioscience by 3.9% in the second quarter. Teachers Advisors LLC now owns 71,829 shares of the company’s stock worth $1,131,000 after acquiring an additional 2,692 shares in the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Meridian Bioscience by 1.1% in the second quarter. TIAA CREF Investment Management LLC now owns 115,208 shares of the company’s stock worth $1,815,000 after acquiring an additional 1,294 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Meridian Bioscience by 11.9% in the second quarter. Ameriprise Financial Inc. now owns 267,557 shares of the company’s stock worth $4,215,000 after acquiring an additional 28,488 shares in the last quarter. Finally, Thrivent Financial For Lutherans increased its position in shares of Meridian Bioscience by 8.0% in the second quarter. Thrivent Financial For Lutherans now owns 25,520 shares of the company’s stock worth $402,000 after acquiring an additional 1,880 shares in the last quarter. 84.94% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Meridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 Shares” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/08/meridian-bioscience-inc-vivo-director-john-mccune-jr-rice-acquires-1000-shares.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply